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Abstract
Shiga toxin (Stx)-producing Escherichia coli (STEC) infection is associated with a broad spectrum of clinical manifestations
that include diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome (HUS). Systemic Stx toxemia is considered to be
central to the genesis of HUS. Distinct methods have been used to evaluate anti-Stx response for immunodiagnostic or
epidemiological analysis of HUS cases. The development of enzyme-linked immunosorbent assay (ELISA) and western blot
(WB) assay to detect the presence of specific antibodies to Stx has introduced important advantages for serodiagnosis of
HUS. However, application of these methods for seroepidemiological studies in Argentina has been limited. The aim of this
work was to develop an ELISA to detect antibodies against the B subunit of Stx2, and a WB to evaluate antibodies against
both subunits of Stx2 and Stx1, in order to analyze the pertinence and effectiveness of these techniques in the Argentinean
population. We studied 72 normal healthy children (NHC) and 105 HUS patients of the urban pediatric population from the
surrounding area of Buenos Aires city. Using the WB method we detected 67% of plasma from NHC reactive for Stx2, but
only 8% for Stx1. These results are in agreement with the broad circulation of Stx2-expressing STEC in Argentina and the
endemic behavior of HUS in this country. Moreover, the simultaneous evaluation by the two methods allowed us to
differentiate acute HUS patients from NHC with a great specificity and accuracy, in order to confirm the HUS etiology when
pathogenic bacteria were not isolated from stools.
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Introduction
Verocytotoxin-producing Escherichia coli (E. coli), also referred to
as Shiga toxin (Stx) -producing E. coli (STEC), infection is
associated with a spectrum of clinical manifestations that include
diarrhea, hemorrhagic colitis, and hemolytic uremic syndrome
(HUS) [1–3]. Systemic Stx toxemia is considered to be central to
the genesis of HUS [2] because there is cumulative evidence
demonstrating systemic Stx-mediated damage to vascular endo-
thelial cells in the kidney, gastrointestinal tract, and other organs
and tissues [4].
Stxs are a family of protein toxins that share a structure of
polypeptide subunits consisting of an enzymatically active A
subunit (approx 32 kDa) that is linked to a pentamer of B (binding)
subunits (approx 7,5 kDa) [5]. The holotoxin binds to the
glycosphingolipid receptors, preferentially globotriaosylceramide
(Gb3), on the surface of eukaryotic target cells and it is internalized
by receptor-mediated endocytosis [6]. The A subunit is proteo-
litically nicked to an active A1 fragment (aprox 27.5 kDa) that acts
on the 28S ribosomal subunit to inhibit protein synthesis [7].
Among the Stxs produced by human STEC isolates, Stx2 and
Stx2c show the highest association with HUS [8]. Stx1 is
serologically distinct from Stx2 (and Stx2c) and these toxins do
not show cross-neutralization by homologous antisera in Vero cell
monolayers [7,9]. On the other hand, Stx2 is completely
neutralized by anti-Stx2c antiserum, whereas Stx2c is only
partially neutralized by Stx2 antiserum [10].
Laboratory diagnosis of STEC O157 infections relies on the
pathogen isolation from stools [8], detection of Stx in the fecal
filtrates [11], and/or anti-Stx serum antibodies [12]. Although
some reports have shown that patients develop rising levels of Stx
antibodies following STEC infection [13–15], little is known about
the nature and duration of the serum anti-toxin response and the
role of these antibodies in immunity. The earliest method used to
test the presence of anti-Stx-antibodies has been the standard
neutralization assay (Stx-Nab), which is tedious and difficult to
standardize. In addition, Stx2-Nab assay has been shown to detect
nonspecific neutralizing activity in serum associated to a
component of the serum high-density lipoprotein fraction, rather
than specific antibodies [16]. Some progress has been made
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(ELISA) [13] and western blot [16,17]. However, the diagnosis of
HUS in Argentina is mainly based on clinical parameters, and
specific microbiological studies are only done by the National
Reference Laboratory from the National Health Surveillance
System [18]. Then, the application of those immunoassays to
detect the presence of specific antibodies to Stx2 for serodiagnosis
and seroepidemiological studies has been very limited but it can be
improved and generalized if simple and inexpensive techniques are
standardized, and show applicability and pertinence in our
country.
Measurement of antibodies to O157 lipolysaccharide has been
widely used for serological diagnosis of HUS associated to E. coli
O157:H7 infection [18–20], because O157:H7 is epidemiologi-
cally the most frequent seropathotype associated to HUS.
However, the improvement of microbiological detection methods
has reported an increasing frequency of HUS cases associated to
non-O157 serotypes, such as O26:H11, O103:H2, O111:NM,
O121:H19, and O145:NM [21,22].
An increasing frequency of anti-Stx antibodies has been
reported in higher-age population which is in general refractory
to HUS [23]. In addition, anti-Stx2 seroreactivity has been
correlated with the absence of symptoms in family outbreaks of
STEC infection [24,25]. This evidence together with the almost
null recurrence of the enteropathic form of this disease, suggest
that HUS resistance may be associated with increasing immunity,
possibly to Stx2.
The objectives of the present study were 1) to develop a
standard antibody ELISA to detect anti-Stx2 B subunit, and a WB
assay against the whole Stx2 and Stx1 proteins; 2) to correlate the
results from anti-Stx2B ELISA with those from anti-Stx2 WB and
to validate them to be used in our population; and 3) to study the
presence of antibodies against Stx2 A and B subunits in normal
healthy children and HUS patients from Argentina.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee of
Children’s Hospital, San Justo, Provincia de Buenos Aires. All
HUS patients and controls were enrolled in this study between
March 2003 and September 2008 after the written informed
consent from their parents had been obtained.
Patients and controls
All children were from the same urban area. The criteria for
HUS diagnosis were microangiopathic hemolytic anemia with
schizocytes, thrombocytopenia (platelet count ,150610
9/L) and
acute renal failure (serum creatinine level higher than the normal
values considering the age of the patient). All patients developed
HUS after gastroenteritis consisting of bloody diarrhea (n=56).
Sixty percent of the children were positive for STEC (Stx2 and/or
Stx2c positive), diagnosed by stool culture. Forty seven percent
were boys and 53% were girls, age range 8 to 108 months;
median, 32 months; mean, 40 months (standard deviation {SD}
26 months). Blood samples (2 ml) were obtained for biochemical
studies by venopuncture into EDTA plastic tubes at hospitaliza-
tion. Plasma samples were immediately separated and stored at
220uC until use.
Plasma samples collected after different times during HUS
follow-up (from 18 days to 213 months after the onset of HUS;
median=51 months; mean=65 months; 1SD=60 months) were
available from 49 patients (37% male, 63% female). Since HUS-
recovered patients (HUSrec) should be followed-up for nephrolo-
gical controls at least up to adolescence, the samples from HUSrec
patients were obtained when they assisted to the out-patient
nephrology department after a non-standard period of time since
the acute disease.
Blood samples from normal healthy children (NHC, n=72)
admitted for routine surgical procedures were collected and
processed identically (age range, 2 to 156 months; median=60
months; mean=59 months; 1SD=50 months). They had no
history of diarrhea for the preceding 6 months and they were not
associated with an outbreak or sporadic case of HUS.
Shiga toxin preparation and purification
The complete gene for Stx2 was amplified by PCR from total
DNA from E.coli O157:H7 C600 (933W) by using the primers
previously reported [26]. The complete gene for Stx1 was
amplified by PCR from total DNA from the same strain E.coli
O157:H7 C600 (933W) with primers upstream (59 GAT ATG
TTA AGG TTG CAG CTC TC-39) and downstream (59 GGG
CTA TTC TGA GTC AAC GG-39). The resulting fragments
(1,422 bp for Stx2 and 1,396 bp for Stx1), which included the
original promoter region, were cloned in pGEMT Easy vector
(Promega, Madison, WI), thus generating the plasmids
pGEMTStx2 and pGEMTStx1. The culture of recombinant E.
coli JM109 strain transformed by the recombinant plasmids
containing the Stx1 or Stx2 sequences, was obtained by incubation
overnight at 37uC with shaking at 200 rpm in Luria-Bertani (LB)
broth (Difco Laboratories, MD) supplemented with 100 mg/ml
ampicilin (Sigma-Aldrich, St. Louis, MO). Bacterial cells were
centrifuged and the resultant pellet was resuspended in PBS
containing 1 mM phenylmethylsulfonyl fluoride (PMSF) protease
inhibitor (Gibco, Grand Island, NY) (PBS-PMSF) and lysed by
sonication. After centrifugation (14,000 rpm, 20 min 4uC) the
supernatant from JM109/pStx2 was precipitated with amonium
sulfate solution (75%), purified as previously described [17] and
stored at 220uC until its usage.
Stx1 was purified by affinity chromatography with commer-
cially available Globotriose Fractogel (IsoSep AB, Tullinge,
Sweden) as previously described [27]. Briefly, 1 ml of the
supernatant from JM109/pStx1 was applied to 1 ml Globotriose
Fractogel column. The column was incubated at 4uC for 2 h and
washed three times with 5 ml of PBS. Stx1 was eluted from the
column with 5 ml of PBS containing 4 M MgCl2. The eluted
material was pooled, dialyzed with PBS, and concentrated by
centrifugation filtration using the Ultra system (Millipore, Bedford,
MA) up to a concentration of 200 mg protein/ml. The
concentrated toxin preparation was examined for homogeneity
by sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE).
Western blot assay to detect anti-Stx 2 and –Stx 1 IgG
(H+L)
This assay was adapted from the method reported by Karmali
et al. [23]. Briefly, a standard concentration of purified Stx2 or
Stx1 (80 mg) was resolved into its A and B subunits by SDS-PAGE,
by using 6% stacking and 17.5% separating gels and electroblotted
onto polyvinylidene difluoride (PVDF) membranes (Bio-Rad
Laboratories, Hercules, CA) overnight (20 v). Membranes were
stained with Ponceau red to confirm protein transfer. After
overnight blocking in Tris buffer (Tris 50 mmol/L; pH 7.4)
containing 5% skim milk and 5% goat serum (Chemicon
International, Billerica, MA), each membrane was cut into
longitudinal strips. The strips were incubated overnight at 4uC
in the plasma specimens diluted 1:100 in Tris buffer containing
5% skim milk and 5% goat serum. After washing, the strips were
Anti-Stx Antibodies in Argentinean HUS Patients
PLoS ONE | www.plosone.org 2 April 2011 | Volume 6 | Issue 4 | e19136incubated for 1 h at 37uC with 1:10000 goat anti-human IgG
(H+L) peroxidase conjugate (Chemicon International) in Tris
buffer containing 3% skim milk and 3% goat serum. After three
washes in Tris buffer, the strips were developed using a
chemiluminiscent detection system (ECL; Amersham Pharmacia
Biotech, United Kingdom). The strips were exposed to a Kodak
AR film (Kodak, Rochester, NY) for 10 min, and the film was then
developed. Each plasma sample (patient as well as control
specimens) was tested at least twice. The results of the WB were
read in a blinded fashion.
Stx2 B subunit (Stx2B)
In order to obtain the Stx2 B subunit, the stx2b gene was
amplified by PCR and cloned as previously described [28]. Briefly,
the stx2b gene was cloned in the pQE-70 vector (QIAGEN,
Germantown, MD) thus generating the plasmid pStx2B. Compe-
tent E. coli DH5a (Bethesda Research Laboratories, Carlsbad, CA)
were transformed with the pStx2B, were grown in LB supple-
mented with 100 mg/ml ampicilin until an OD600 of 0.6 at 37uC
with shaking (200 rpm), and then were induced with 1 mM
isopropyl b-D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich)
over 5 hours. The supernatant was filtered (0.22 mm) and treated
with ammonium sulphate to 75% saturation. The precipitate was
collected by centrifugation, then resuspended in PBS-PMSF,
dialyzed overnight at 4uC and stored at 220uC until its usage.
Detection of anti-Stx2B IgG by ELISA
This assay was adapted from the method previously reported
[24] with some modifications. Briefly, 96-well microtiter plates
(GBO, Germany) were coated by incubating overnight with 0.5 mg
Stx2B per well in 15 mM carbonate, 25 mM bicarbonate (pH 9.6)
at 4uC. As antigen controls, wells were incubated with 0.25 mg
supernatant from DH5,alpha. (pQE-70), which lacks the B
subunit sequence, or PBS, and they gave equivalent results. Then,
250 ml of PBS containing 1% BSA was added to each well and the
plates were incubated for 2 h at 37uC. The plates were washed
three times with PBS containing 0.1% Tween 20 and incubated
for 2 h at 4uC with the plasma samples diluted 1/4000 in PBS
containing 0.05% Tween 20 and 0.5% BSA. After three washes,
the plates were incubated overnight with 1/4000 goat anti-human
IgG horseradish peroxidase conjugated in PBS containing 0.05%
Tween 20 and 0.5% BSA at 4uC. As control for the unspecific
stuck of the secondary antibody, 100 ml of PBS was added instead
of plasma samples. After three more washes, 100 ml of substrate
solution (0.1 M citrate-phosphate pH 5, 1 mg/ml o-phenylenedi-
amine dihydrochloride [OPD] (Sigma-Aldrich), 30% H2O2) was
added to each well and incubated for 20 min at room temperature
in darkness. The reaction was terminated by the addition of 50 ml
of 4 N sulfuric acid and the optical density values at 492 nm
(OD492) were measured in a microplate ELISA reader. To obtain
the net ELISA value, each plasma specimen was tested in
duplicate and the mean OD492 value was calculated subtracting
the OD492 value of the test well from the OD492 value of the
antigen control well. In order to determine the cut-off value for the
ELISA test, we calculated the mean value + 2SD from those
plasma samples from NHC group that did not show specific bands
by WB studies (mean=0.119, 2SD=0.107, n=18). Taking into
account the high prevalence of Stx antibodies in the NHC, we also
evaluated plasma samples from a small group of newborn children
(n=5) by ELISA test (OD492 mean=0.116, 2SD=0.087), and the
mean value + 2SD for them was not different to that for NHC
group. Thus, OD492=0.226 was considered as the cut-off for the
ELISA test and absorbance values below this OD were considered
as IgG-negative for Stx2.
Statistical methods
Frequency values were compared with the Chi-square test for
independence and trend (two by three tables) or Fisher’s exact test
(two by two table) as indicated. Median values were compared
with Wilcoxon Signed Rank test as indicated.
Results
Antibodies against the A and/or B subunit of Stx2 and
Stx1
Purified Stx2 and Stx1 were resolved by SDS-PAGE, after
transferring it onto PVDF membranes, and two bands corre-
sponding to the molecular mass of A and B subunits from each
toxin were identified with either control mouse-polyclonal
antibodies anti-Stx2 or anti-Stx1 (Fig. 1A and B). Human plasma
that were positive for Stx2 (Fig. 1A) were reactive with either the A
subunit alone, the B subunit alone, or both subunits. Although the
intensity of the reactivity was variable, the strongest signals were
detected in HUS or HUSrec plasma. Human plasma that were
positive for Stx1 antibodies (Fig. 1B) were reactive with either the
A subunit alone, or both subunits. At sample dilution assayed none
of Stx2-positive plasma were positive for Stx1.
Frequencies of Stx2 and Stx1 antibodies
Plasma samples reacting with no subunits or with the A and/or
B subunit of Stx2 and/or Stx1 are shown in Fig. 2.
When samples were tested against Stx1, a similar low frequency
of reactive samples was observed in all clinical groups (Fig. 2A)
(HUS=5%, HUSrec=14%, NHC=8%; p=0.55, Chi-square
test). All positive plasma samples were reactive only against Stx1-A
subunit, except one that was reactive for both, A and B subunit of
Stx1.
The overall frequency of reactive plasma with at least one
subunit of Stx2 in NHC group (67%) was significantly lower than
the frequency in HUS (86%) and HUSrec (82%) clinical groups
(Fig. 2B) when compared by the Chi square test (p,0.05).
HUS patients developed antibodies against both subunits of
Stx2 more often than NHC control group (HUS=56%
Figure 1. Antibodies against Stx2 and Stx1. Representative
immunoblot strips from HUS or healthy children plasma reactive to
Stx2 (A) and Stx1 (B) are shown. A) Lane 1 shows a mouse-polyclonal
plasma reactive against Stx2 A and B subunits; positive human plasma
showed reactivity to either the A subunit alone (lane 2), the B subunit
alone (lane 3), or both subunits (lane 5). Samples that showed a
complete absence of binding signal were considered negative (lane 4).
B) Lane 1 shows a mouse-polyclonal plasma reactive against Stx1 A
subunit, and lane 5 shows a monoclonal hybridoma reactive against
Stx1-B subunit (13C4, ATCC CRL-1794). Positive human plasma showed
Stx1-binding signal to either the A subunit alone (lane 2) or both
subunits (lane 4). Samples that showed a complete absence of binding
were considered negative (lane 3). Each plasma sample was assayed at
least twice. When discrepancy between the results was observed, a
third WB was made in order to rule out the wrong result.
doi:10.1371/journal.pone.0019136.g001
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was lost during follow-up period (HUSrec=39%; p=0.39,
Fisher’s exact test) (Fig. 2B). Considering plasma samples reactive
to the A subunit, alone or together with the B subunit, we found
that HUS patients presented antibodies against the Stx2 A subunit
significantly more often than controls did (HUS=70%,
NHC=47%, p,0.01, Fisher exact test). This increase in the
frequency of Stx2 A subunit antibodies was still evident during the
follow-up period (HUSrec=66%, p,0.05 vs NHC, Fisher’s exact
test). Acute HUS patients also showed a significantly higher
frequency of antibodies against the B subunit than NHC patients
(HUS=72%, NHC=53%, p,0.05, Fisher’s exact test), but this
difference was lost during follow-up (HUSrec=53%) (Fig. 2 B).
Antibodies against Stx2 B subunit measured by an ELISA
assay
The anti-Stx2 B subunit antibody response was also examined
by an ELISA test, by using purified Stx2 B subunit as the coating
protein. OD492 values for each plasma sample from different
clinical groups tested at 4,000-fold dilution are shown in Fig. 3A.
Absorbance values for each sample were plotted according to
their WB result (segregated as positive or negative for B subunit),
and into their corresponding clinical group (Fig. 3A). Although
these results showed that WB-positive plasma samples from
different clinical groups had a wide range of OD492 absorbance
when assayed by ELISA, the median absorbance of positive
samples of HUS group was higher than the NHC group
(HUS=0.51, n=35; NHC=0.40 n=23; p,0.01, Wilcoxon
Signed Rank test). However, it was not significantly different to
the HUSrec group (HUSrec=0.45, n=17; p=0.051, Wilcoxon
Signed Rank test).
In addition, Fig. 3A shows that plasma from 35 out of 39 HUS
patients presented a reactive band against Stx2 B subunit by WB
and had an absorbance ELISA value over the cut-off (89.7%),
while only 1 out of 12 HUS samples was non-reactive by the WB
assay and had an absorbance over the cut-off value (8.3%),
confirming the strength and specificity, respectively, of the
combined test-assaying.
On the other hand, plasma from 17 out of 27 HUSrec children
were reactive for Stx2 B subunit by WB and positive by ELISA
assay (63.0%), and only 23 out of 35 NHC children showed
positive results by both ELISA and WB assays (65.7%) (Fig. 3A).
When WB-negative sera against the Stx2 B subunit were assayed
by ELISA, we observed very low and similar OD492 values in the
three clinical groups.
Finally, Fig. 3B shows that HUS group had the highest
percentage of positive plasma samples by the two methods
(p,0.0005 vs NHC and HUSrec, Chi-square test), suggesting
that the combination of both techniques add strength to the result.
Kinetics and duration of antibody response against Stx B
subunit in HUS patients
Since HUS group showed higher frequency of positive samples
for B subunit by WB (Fig. 2) and higher ELISA titers (Fig. 3A and
3B) than HUSrec group, we plotted ELISA titers over time (Fig. 4).
Although plasma samples from HUSrec group were not
collected after a standard predetermined period of time after the
onset of disease, it can be clearly stated that absorbance levels of
anti-Stx2 B subunit IgG by ELISA were higher during the first
year after illness, following a slow decrease over time. It is
important to highlight that patients after more than 10 years of
follow-up were also included in this study, and they still have
reactivity against B and/or A subunit.
Discussion
In spite of the high circulation of STEC strains in Argentina, in
particular those producing Stx2 [8], local information about the
frequencies of anti-Stx2/Stx1 antibodies in HUS cases and healthy
children is very limited. This is because, at least in part, the
evaluation of anti-Stx2/Stx1 antibodies is not routinely done by
clinical laboratories. Although the presence of neutralizing activity
in HUS patient’s sera by using Vero cell monolayers is routinely
performed by the National Reference Laboratory from the
National Health Surveillance System, it is known that a very low
neutralizing activity is generally observed and not in all patients
[12] . For this reason, several authors have reported more sensitive
tests such as ELISA [29] or immunoblotting assay [16,23] for anti-
Shiga toxin antibodies detection. Our work indicates that Western
blotting and ELISA can be successfully used also in Argentina to
Figure 2. Frequencies of Stx2 and Stx1 antibodies. The frequency of reactive plasma samples against Stx1 (A) or Stx2 (B) in age-matched
normal healthy children (NHC) (n=72), in patients with enteropathic HUS at acute period (n=56), or after recovery (HUSrec) (n=49) are shown. Each
bar represents non-reactive plasma samples (light grey) or samples reacting with only B subunit (black), only A subunit (striped), or with both
subunits (A and B) (white) of Stx1/Stx2 assayed by WB analysis. A) Significant differences were not observed between the groups (p=0.55, Chi-square
test). B)
#p,0.05 vs HUS and HUSrec, Chi-square test; *p,0.05 vs HUS and HUSrec, ** p,0.01 vs NHC, Fisher’s exact test.
doi:10.1371/journal.pone.0019136.g002
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both methods combine different antigenic proteins: B subunit of
Stx2 or the whole holotoxin, either native or denatured, they
probably detect different antibodies thus enhancing the spectrum
of antibody detection. It is interesting to highlight that the
association between the positive results obtained by ELISA and
WB techniques was stronger in HUS group than in NHC or
HUSrec groups (Fig. 3B), probably as a consequence of higher
antibody titers in plasma from HUS group than those in plasma
from NHC or HUSrec groups. Moreover, the simultaneous
evaluation by the two methods allowed us to differentiate HUS
acute patients from normal healthy children with a great specificity
and accuracy, in order to confirm the HUS etiology when non-
pathogenic bacteria were isolated from stools.
Serological examination of sporadic HUS cases provide a useful
tool for diagnosis of STEC infection wherein STEC isolates or free
fecal Stx2 are not detected [30]. We found a very similar
frequency of antibodies against Stx2 in HUS patients and HUSrec
group (86% and 82%, respectively), even when several years had
elapsed since their illness. In comparison, only 67% NHC patients
showed anti Stx2-antibodies. Although this frequency was
significantly lower compared to those in HUS patients, it is
important to point out that it was significantly higher than the
frequencies reported in healthy children from other countries such
as Germany (10%) [17] or Canada (46%) [23] for an age-matched
population. This result could be ascribed to the high circulation of
Stx2-producing strains in Argentina [8,31], and could be
associated to the HUS endemic behavior in this country. The
existence of a large non-symptomatic population of adults that
carry the pathogenic strains could contribute to this behavior
through a person-to-person transmission. Indeed, STEC-positive
adults or children are often detected when a household child
undergoes STEC-associated bloody diarrhea or HUS [32].
Moreover, 51% of HUS household contacts have been reported
to have neutralizing anti-Stx2 antibodies in Argentina [25].
Reports demonstrating diarrheal illness in a family member as a
risk factor for developing HUS in Canada also support person-to-
person transmission [33–35].
In sharp contrast, the percentage of positive plasma for Stx1 was
below 15% in both, NHC and HUS Argentinean groups.
Moreover, these frequencies are similar to those found in Europe
[36] and in the United States [13] comparing both, healthy and
HUS populations. The much higher frequency of antibodies to
Stx2 than to Stx1 in controls together with the observation of a
high prevalence of Stx2/Stx2c-producing STEC in beef cattle
[37], as well as in stools from post-enteric HUS cases in Argentina
[8,31], suggest that Stx2-producing strains are much more
common than Stx1-producing ones.
Regarding the specificity of Stx2 antibodies, we observed that
HUS patients (acute+HUSrec) showed higher frequencies of anti-
Stx2 A subunit antibodies compared to controls, similarly to
previous reported data in other countries [2,25]. Moreover, an
Figure 3. Antibodies against Stx2 B subunit measured by
ELISA. A) Absorbance values by ELISA assay detecting anti-Stx2 B IgG
in plasma from NHC, HUS or HUSrec groups were segregated according
the result (positive or negative) obtained by WB for the Stx2 B subunit.
OD492 values obtained are individually depicted. The horizontal whole
line (OD492=0.226) indicates the cut-off value to consider a plasma
sample as positive or negative. B) Relationship between results of anti-
Stx2 B antibodies obtained by ELISA and WB assays. Bars represent the
frequency of positive plasma against Stx2 B subunit by the two
methods (light grey), positive sera by at least one of the methods
(white) and negative by the two methods (dark grey) in normal healthy
children (NHC), HUS patients at acute period (HUS) or after recovery
(HUSrec). *p,0.0005 vs NHC and HUSrec, Chi-square test.
doi:10.1371/journal.pone.0019136.g003
Figure 4. Correlation of anti-Stx2 B IgG ELISA plasma values
from HUSrec patients with the time since the enteropathic HUS
episode. OD492 values obtained at different times (months) since the
HUS episode are individually depicted. The regression line 6 2SD is
indicated by the whole and dashed lines, respectively. Correlation
coefficient, r=20.41, p,0.005.
doi:10.1371/journal.pone.0019136.g004
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a long lasting humoral immune response, particularly against the
A subunit. This fact has several theoretical and practical
implications. First of all, these results go against the hypothesis
that Stx2 is cytotoxic for B lymphocytes, preventing the induction
of anti-Stx2 antibody response, already previously questioned by
Barrett et al. [13].
Secondly, because STEC/Stx2 is highly endemic in Argentina,
it is possible that an asymptomatic or auto-limited gastrointestinal
infection with pathogenic strains was insufficient to stimulate a
detectable antibody response to Stx2 A subunit. On the other
hand, whether the anti-Stx2 A subunit response observed in HUS
children would result from a booster response during a second
exposure, or as consequence of a high enough bloodstream
concentration of Stx2, is a matter for discussion. Although we
used anti-IgG as secondary antibody in this study, it reacted
against the heavy- and light-chain, so the WB could detect not
only IgG but also, potentially, IgM and IgA. It is likely, however,
that among the patients with HUS we were dealing in the acute
phase sera with IgM and IgG and in the follow-up and the
control group we were dealing with IgG because they were all
asymptomatic.
The persistence of anti-Stx2 antibodies was investigated in 49
samples from HUSrec patients at different follow-up periods. The
frequency of anti-Stx2 reactive plasma in HUSrec group was
similar to the HUS acute group, suggesting a specific antibody
response which was long-lasting. This finding is in sharp contrast
with the short persistence of the anti-Stx antibodies in Germany.
In fact, Ludwig et al. [17] found that the antibody levels of 50% of
the patients with HUS had decreased below the respective cut-off
levels at 3 months after the onset of diarrhea. We do not know if
the longer duration of the antibody response in Argentinean
patients is supported by the continuous antigen re-stimulation, or
if it is related to methodological differences in the used assays.
However, the antibody response against the Stx2 B subunit tends
to decrease faster than the antibody response against Stx2 A
subunit. In fact, not only the frequency of anti-Stx2 B antibodies
decreased in HUSrec patients, but also their ELISA titer
decreased over time. Consequently, HUSrec group showed an
increased frequency of positive samples for the A subunit
compared to the NHC group (Fig. 2B) (HUSrec=66% vs
NHC=47%), while there were not differences in the frequency
of positive samples for the B subunit (HUS rec=53% vs
NHC=53%). These findings strengthen the need for investigating
individual samples sequentially.
Although the biological significance of antibodies against both
Stx2 subunits is not known and requires further study, recent
evidence suggests that specific antibodies for Stx2 A subunit may
be important for protection [38]. In fact, monoclonal antibodies
directed to the Stx2 A subunit have been proved to be as
protective or more than those directed to the B subunit [39,40].
Although the involved mechanisms are still a matter for
discussion, it has been recently reported that anti-Stx2 A subunit
antibodies interfere with the retrograde transport of the toxin,
and may interact with Stx2 when it is still bound to membrane
receptors [41]. In addition, antibodies directed to Stx2-A subunit
as opposed to those directed against the B subunit, have broad-
spectrum activity that includes other Stx2 variants, such as Stx2c
[39,42].
In conclusion, this is the first report describing seroepidemio-
logical data about anti-Stx antibodies in the pediatric Argentinean
population, this is in healthy and HUS-suffering children, through
accurate and sensitive techniques such as ELISA and WB. This
information not only could provide comprehensive immunological
data as a basis for future immunization schedules to Stx, but also
encourage laboratories from the National Health Surveillance
System to standardize both techniques in order to evaluate a
bigger population that include individuals from areas with
different incidence of HUS.
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